Osteomyelitis of Jaw
Conditions
Brief summary
The goal of this clinical trial is compare the efficacy of oral and IV antibiotics in the treatment of orofacial osteomyelitis. The main question it aims to answer is: Are oral antibiotics as effective as IV antibiotics in the treatment of orofacial osteomyelitis. Participants, once diagnosed with osteomyelitis, will be started on oral antibiotics for their treatment. Participants will follow up with oral and maxillofacial surgery clinic accordingly and their progression and compliance will be monitored.
Detailed description
We plan to conduct a randomized controlled open label trial of PO versus IV antibiotics in treatment of patients with osteomyelitis of the jaws. The clinicians caring for the patient will decide what antibiotics to give to the patient and the route or antibiotic therapy will be oral unless this route of administration fails and the patient does not wish to extend the oral antibiotics route. After thorough discussion of the risks, benefits, and alternatives, a consent form is reviewed and signed. The clinicians' choice of antibiotic prescribed will be according to the common practices and standards, with modifications, when necessary, based on local antibiotic guidelines, and in consultation with Infectious Disease (ID) team at our institute when needed. Participants will include patients with osteomyelitis of the jaws diagnosed by the Oral and Maxillofacial Surgery (OMFS) Department of the University of Louisville for eligibility. We will determine if the patient meets the inclusion and exclusion criteria, and, if the patient is willing, a study member will obtain informed consent. If patients provide informed consent, we will then record the clinical diagnosis and demographic data. These forms will be stored in our clinic and scanned in patient's medical records for future reference. We will see the patients according to our routine schedule in our clinic. This schedule includes the primary consultation appointment, admission, and inpatient surgery, the first follow-up 24-72 hours after discharge from hospital, one week follow up afterwards, and then follow-ups at two weeks, one month, 2 months, and then as needed on a case-based basis. Outcomes of the treatment with oral antibiotics will be compared to the historical outcomes of patients treated with IV antibiotics at the University of Louisville oral and maxillofacial surgery clinic.
Interventions
DRUGAmoxicillin-clavulanate 875mg/125mg q12hrs
Oral antibiotic used based on indication
DRUGoral clindamycin 300mg q6hrs
Oral antibiotic used based on indication
DRUGLevofloxacin 750mg QID
Oral antibiotic used based on indication
Sponsors
Osteo Science Foundation
University of Louisville
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
The participant must meet each of the following inclusion criteria: 1. Clinical presentation of: 1. localized pain OR 2. localized erythema OR 3. temperature \>38.0ºC OR 4. a discharging sinus or wound AND 2. willing and able to give informed consent AND 3. aged 18 years or above AND 4. the patient has received 7 days or less of intravenous therapy after an appropriate surgical intervention regardless of pre-surgical antibiotics 5. has a life expectancy \> 1 year AND 6. has 1. native osteomyelitis of the jaw (no hardware), either hematogenous or contiguous (odontogenic, trauma, etc) OR 2. hardware or bone graft infection treated by debridement and retention, or by debridement and removal The
Exclusion criteria
would consist of: 7. sepsis, septic shock, concomitant infection, or any need for prolonged hospitalization OR 8. tissue diagnosis other than dead bone OR 9. Staphylococcus aureus bacteremia on presentation or within a month OR 10. bacterial endocarditis on presentation or within the last 6 months OR 11. mild osteomyelitis not usually requiring prolonged IV antibiotics OR 12. when only IV form is available for a given antibiotic OR 13. the patient is unlikely to comply with trial OR 14. evidence of mycobacterial, fungal, parasitic, or viral etiology OR 15. participating in another clinical trial OR 16. pregnant patients OR 17. cognitively impaired patients or any situation in which informed consent cannot be obtained OR 18. incarcerated patients OR 19. patients with Chronic Nonbacterial Osteomyelitis (CNO) or Chronic Recurrent Multifocal Osteomyelitis (CRMO) OR 20. history of radiation to the jaws OR 21. history of bisphosphonate intake OR 22. patient less than 18 years of age
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Definite failure of antibiotic therapy in the treatment of orofacial osteomyelitis | 6-8 weeks | The primary outcome will be a definite failure of antibiotic therapy indicated by one or more of the following (only resolution or failure will be recorded as the outcome): 1. formation of a draining sinus tract arising from bone 2. superficial spreading erythema, treated as cellulitis 3. recurrence of frank pus 4. no resolution of clinical signs and symptoms 5. development of sepsis 6. need for second surgery within 3 months (and if the first surgery is deemed adequate) 7. recurrence of infection within 6 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentages of patients unable to complete treatment | 3-6 months | Total number of patients that are unable to complete the proposed treatment due to any reason. |
| Patient Quality of life during therapy | 3-6 months | Evaluate quality of life of patients receiving therapy. Quality of life will be evaluated by the EQ-5D assessment. Based on the results, the assessment is scored from 0-1. 1 represents the best possible health and 0 represents the worst possible health. |
| Treatment cost | 3-6 months | Assessment of total monetary accumulation (in dollars $) per patient based on all interactions including the following: a) length of inpatient hospital stay, b) frequency of outpatient visits, c) inpatient and outpatient treatment costs |
| Incidence of Clostridium difficile associated diarrhea | 3-6 months | Patients that develop the opportunistic infection clostridium difficile related to long term use of antibiotics for their treatment. Infection will be confirmed by stool sample. |
| Adherence | 3-6 months | Adherence will be assessed by the Medication Event Monitoring Systems (MEMS) in participants. The MEMS system sensor in the pill bottle top detects opening and closing and records these events with a date stamp which helps verify whether patients accessed their bottles according to the schedule. |
Countries
United States
Contacts
Primary ContactSuzanne Barnes, DMD
Backup ContactChad Davidson, DMD
Outcome results
None listed